Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Ability of SpikoGen®, an Advax‐CpG adjuvanted recombinant spike protein vaccine, to induce cross‐neutralising antibodies against SARS‐CoV‐2 variants

Immunology(2023)10.1111/imm.13661Source: DataRank Database

Ability of SpikoGen®, an Advax‐CpG adjuvanted recombinant spike protein vaccine, to induce cross‐neutralising antibodies against SARS‐CoV‐2 variants is a research paper published in Immunology (2023). On theSindex it has a DataRank of 0. It has been cited 12 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access12 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 2.02)OA: bronzeTopics (31)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (6)

Anna Antipov ORCID,Greiciely O. André ORCID,Saghar Barati ORCID,Hamidreza Kafi,Nikolai Petrovsky ORCID

Live enrichment

PubMed:37199229 PMC:PMC10524547 OpenAlex:https://openalex.org/W4377011856

National Institute of Allergy and Infectious Diseases

Grant: HHS‐N272201400053C

National Institute of Allergy and Infectious Diseases

Grant: HHSN272201800044C

National Institute of Allergy and Infectious Diseases

Grant: HHSN272201800024C

NIAID NIH HHS

Grant: HHSN272200800039C

NIAID NIH HHS

Grant: HHSN272201400053C

CinnaGen

FWCI

2.02

Citation Percentile

0.9%

Citation Trend

2023

2024

2025

bronzeLicense: http://onlinelibrary.wiley.com/termsAndConditions#vor

journalhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/imm.13661

publisherhttps://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/imm.13661

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1111/imm.13661

journalhttps://doi.org/10.1111/imm.13661

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37199229

Fields of Study

SARS-CoV-2 and COVID-19 ResearchBacillus and Francisella bacterial researchViral Infections and Outbreaks Research

MeSH Terms

Broadly Neutralizing AntibodiesCOVID-19SARS-CoV-2COVID-19 VaccinesAdjuvants, ImmunologicAdultAntibodies, ViralHumansInulinVaccines, SyntheticVaccines, SubunitAntibodies, NeutralizingSpike Glycoprotein, Coronavirus

Keywords

Recombinant DNAAntibodyNeutralizationBooster doseMedicineAdjuvantPlaceboVirologyImmunologyTiterBiologyAntibodiesLungImmunotherapyVaccination

Sustainable Development Goals

SDG 0: Good health and well-being

Ability of SpikoGen®, an Advax‐CpG adjuvanted recombinant spike protein vaccine, to induce cross‐neutralising antibodies against SARS‐CoV‐2 variants

FAIR Checklist

Authors (6)

Funding (6 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)